ISRCTN75383472: Survey of the current management of secondary hyperparathyroidism in patients with end-stage renal disease undergoing dialysis in the UK NHS

Participant Flow



Baseline Characteristics

Table 1 Baseline characteristics of patients, n=2,361

Patient characteristic		n	%
Sex			
	Female	937	39.7
	Male	1424	60.3
Age (years)			
	<20	3	0.1
	20-29	56	2.4
	30-39	134	5.7
	40-49	254	10.8
	50-59	373	15.8
	60-69	528	22.4
	70-79	623	26.4
	≥80	390	16.5
Ethnicity			
	White	1743	73.8
	Black	52	2.2
	Asian	176	7.5
	Chinese	10	0.4
	Other	18	0.8
	Not known	362	15.3
Previous parathyroidectomy		148	6.3
Type of dialysis			
	Haemodialysis	2068	87.6
	Peritoneal dialysis	293	12.4
Time on dialysis, months (median and IQR)			
	Haemodialysis*	2066	39 (18.4-75.6)
	Peritoneal dialysis*	285	25 (12.6-44.6)

*Data unavailable for 2 patients on haemodialysis and 8 patients on peritoneal dialysis

Outcome Measures

Table 2 Primary outcome - Stipulated biochemical markers of secondary hyperparathyroidism (SHPT) within target range at most recent measurement prior to data collection (unless otherwise stated in the table)

Target range achieved for stipulated biochemical markers	n	%
Overall		
2 biochemical markers, n=2,158	1,328	61.5
3 biochemical markers, n=1,509	382	25.3
According to guidelines		
UK Renal Association Clinical Guidelines* at most recent measurement, n=1,509	165	10.9
UK Renal Association Clinical Guidelines* at most recent measurement AND 3 months prior to data collection, n=1,231	41	3.3
National Kidney Federation Kidney Disease Outcome Quality Initiative (KDOQI) Guidelines† at most recent measurement, n=1,509	166	11.0
National Kidney Federation Kidney Disease Outcome Quality Initiative (KDOQI) Guidelines† at most recent measurement AND 3 months prior to data collection, n=1,231	38	3.1
Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines‡ at most recent measurement, n=1,509	343	22.7
Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines‡ at the most recent measurement AND 3 months prior to data collection, n=1,231	135	11.0

* Serum phosphate (1.1-1.8 mmol/L), adjusted calcium (2.2-2.5 mmol/L), parathyroid hormone (16-32 pmol/L)
† Serum phosphate (1.13-1.78 mmol/L), adjusted calcium (2.1-2.4 mmol/L), parathyroid hormone (16.5-33.0 pmol/L), calcium phosphate product (<4.5 mmol/L)
‡ Serum phosphate (0.8-1.45 mmol/L), serum calcium (2.1-2.55 mmol/L), parathyroid hormone within 2-9 times the upper limit of the assay used

Adverse Events
No adverse events were identified by the investigators during the data extraction for this study.